Resources - Selecta Biosciences

Publications

Validated and peer-reviewed research

Our research is validated by a long track record of peer-reviewed publications in high-impact journals in collaboration with our industry and scientific partners.

1/2022

Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’?

Taylor & Francis Online

Takashi Kei Kishimoto

1/2022

Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia

Nature Communications

5/2021

Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles

Frontiers in Immunology

5/2020

Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies

Frontiers in Immunology

10/2016

Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles

Nature Nanotechnology

10/2018

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector readministration

Nature Communications

5/2023EULAR 2023

Safety & Efficacy Of Sel-212 in Patients with Gout Refractory to Conventional Treatment: Outcomes From Two Randomized, Double Blind, Placebo-controlled, Multicenter Phase III Studies

Herbert S.B. Baraf, Alan Kivitz, Sheri Rhodes, Sheldon Leung, Olu Folarin, Tania Gonzalez-Rivera, Joanna Sobierska, Jacquie Christie, Anand Patel, Wesley DeHaan, Rehan Azeem, Peter G. Traber

5/2022ASGCT 2022

Combination of ImmTOR Tolerogenic Nanoparticles and IL-2 Mutein Synergistically Inhibits the Formation of Anti-AAV Antibodies

Takashi Kei Kishimoto, Christopher Roy, Alicia Michaud, Gina Rizzo, Teresa Capella, Sheldon Leung, and Petr Ilyinskii

5/2022ASGCT 2022

Mechanisms, monitoring, and mitigation of host immune responses to AAV gene therapy vectors

Takashi Kei Kishimoto

4/2022ASGCT 2022

ImmTOR combined with B cell-targeted therapies provides synergistic activity in mitigating anti-AAV capsid antibody responses and enables repeated vector dosing

Petr Ilyinskii, Christopher Roy, Alicia Michaud, Gina Rizzo, Teresa Capela, Sheldon Leung and Takashi Kei Kishimoto, Selecta Biosciences, 65 Grove St, Watertown, MA USA 02472

4/2022ASGCT 2022

Effect of tolerogenic ImmTOR nanoparticles on the formation of anti-AAV8 antibodies in mice, nonhuman primates, and healthy human volunteers

Peter G. Traber, Shari Gordon, Petr Ilyinskii, Sheldon Leung, Teresa Capela, Alicia Michaud, Holly Schroeder, Tanika Williamson, Gina Rizzo, Canwen Jiang, David Farve, Lloyd Johnston, R. Jude Samulski, Takashi Kei Kishimoto, Selecta Biosciences, 65 Grove Street, Watertown, MA 02472, USA; AskBio HQ, 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, NC 27709, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

10/2021ESGCT 2021

Enhanced level and durability of AAV transgene expression and mitigation of anti-capsid neutralizing antibodies by ImmTOR tolerogenic nanoparticles in nonhuman primates

Takashi Kei Kishimoto, Stephanie Elkins, Teresa Capela, Gina Rizzo, Petr O. Ilyinskii, and Sheldon S. Leung